-- 欧盟周四宣布了一项新的6亿欧元（约合7.04亿美元）的资金计划，旨在支持跨境能源基础设施项目，以加强能源安全并加速向清洁能源转型。 这笔资金来自“连接欧洲能源基金”（Connecting Europe Facility for Energy），将用于支持跨多个国家的项目的筹备研究和建设工作。 该计划由气候、基础设施和环境执行机构负责管理，申请截止日期为2026年9月30日，预计将于明年初公布结果。 该计划是欧盟第二批“共同利益项目”和“互利项目”名单中的首轮资助，这些项目旨在加强欧盟内部以及与邻国之间的跨境能源联系。 欧盟能源与住房专员丹·约根森表示，此次资金投入正值欧洲持续应对能源市场波动之际。 “我们正处于一场新的能源危机之中，因此迫切需要加强能源体系建设并整合市场，”约根森表示。“这对于降低能源成本、提升竞争力以及整合更多本土可再生能源至关重要。” 被指定为“优先互联项目”（PCI）的项目涉及连接至少两个欧盟成员国的基础设施，而优先互联项目（PMI）则扩展欧盟国家与非欧盟邻国之间的联系。 PCI 或 PMI 项目可受益于跨欧洲能源监管网络（TENER）的加速审批流程，以及更优的监管待遇和欧盟资金申请资格。 该计划在 2021-2027 年期间的总预算为 58.8 亿欧元。
Related Articles
Mining & Metals
Agnico Eagle Q1 Record Adjusted Net Income of U$1,706 million or $3.41 per share
$AEM.TO
Treasury
TD Bank Group Issues 150 Million Swiss francs Green Bond
Toronto-Dominion Bank (TD.TO) after the close Thursday said it issued its seventh sustainable-labelled bonds for 150-million Swiss francs. The bank said its total sustainable bond issuances have now exceeded C$5.2 billion since 2014."TD's first European green bond continues building the strength of our sustainable financing program, helping us support clients pursuing sustainable investment in a new jurisdiction," said Nicole Vadori, head of sustainability at TD.TD shares closed up $3.40 at $146.33 on Toronto Stock Exchange.
$TD$TD.TO
Research
Research Alert: Amgn Q1 Tops Estimates Driven By Diversified Growth And Pipeline Investments
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.
$AMGN